EAST VALLEY UROLOGY CENTER Of ArizonaPLC’s Post

#woundcare & #labs 🛑 Important ⏱ as many #membrane #providers are being taken off the list effective September 17th. #ruralhealthcare #communityhospitals #clinics #snfs #assistedliving #communitybasedcare All #options to bring inhouse from #outcomes⬆, #roi⬆, #revenue 💲 6-7M ⬆ , AND #qualitycare⬆ Should be Considered as Many, if not Most #ruralhospitals, #clinics, #nursinghomes #survival depends on it❗ 1️⃣ #lab - #rsv #flu 2️⃣ #wounds ⬇ 3️⃣ #uti ⬇ 4️⃣ #catheter ⬇ 5️⃣ #readmissions ⬇ Call for information at 817-583-3855 c Brian Mericle

“We have nowhere near the capacity to manage all those patients” New research from the US shows that specialists would struggle to cope with the high number of patients with steatotic liver disease. This is largely due to 90% of these patients being overweight, and about 50% of those requiring disease management. In an ideal world, we'd have a system that could detect and manage all these patients, but economic challenges stand in the way. That's where Fatty Liver Alliance and Geoff Red (MSOD) are spot on. At Evido, we are addressing this challenge with a core focus on the entire patient journey and ensuring a sustainable patient pathway from primary care to specialist care. We are dedicated to enabling efficient and affordable detection and management of these people – thereby bridging the gap between the ideal and the real world. 🚀 #datadrivendiagnostics #healthtech #liverdiagnostics

#ESMOVirtualPlenary: A first analysis from IMADGIST shows disease-free survival benefit with 6 years of maintenance therapy with imatinib compared to the 3-years standard of care.  According to Hans Gelderblom, these additional data showing a median progression-free survival (PFS) of 36 months after imatinib reintroduction in the 3-year arm need to be further confirmed by mature overall survival data at a long-term follow-up. Additionally, he highlights that the choice to pursue a prolonged regimen depends on the risk-benefit profile of the adjuvant therapy, since the #DFS benefit of the prolonged adjuvant therapy is not without impact to patients   Read the news on the #ESMODailyReporter  👉 https://lnkd.in/dzef4dXR #RareCancer #GIST  

Adj imatinib in GIST: 3 or 6 y?

Wins in DME So dual pathway block is better ANG2 is important in the progression of PCDR to DR Both VEGFA and ANG2 are bad actors Vabysmo blocks both Effacy matters

Cardiac Action Potential #paramedic #paramedicstudent #paramedicproblems #ems #emtstudent #emtschool #emtlife #studentparamedic #paramediclife #emt #paramedicstudents #paramedico

Physician specialists are calling for help now, on the front lines of MASLD and MASH treatment. Geoff Red (MSOD), Franchise Head of Gastroenterology at Spherix Global Insights and Michael Betel have this important discussion about their current research with Gastroenterologists and Hepatologists. "In our survey, Doctors told us that 90% of MASLD/MASH patients fall in the 'overweight' category. Fifty percent in the extremely overweight, 40% in the overweight, and...10% in the lean MASLD/MASH." "We just do not have anywhere near the capacity to handle all of these patients." Multi-disciplinary intervention and care will be needed by these patients. There are also opportunities for tech companies to step up and help patients learn about their own condition. #obesity #MASLD #MASH #NAFLD #NASH #glp1 #liverhealth

CytoSorbents Corporation Reports Analysis from the STAR-T Study of DrugSorb-ATR to Reduce Perioperative Bleeding and the DSMB’s Recommendation #cytosorbents #drugsorbatr #perioperativebleeding #medtech #start #usfda #healthcanada #efficacy #patients #ticagrelor #cabgsurgery #1ep #dsmb

ICYMI: Watch our free #CME program with The American Macular Degeneration Foundation to understand the barriers preventing people with #nAMD or #DME from fully benefiting from anti-VEGF therapies ➡️ https://bit.ly/3VStRxP 🏷️ #MedEd #MedicalEducation #CME24

NeurAxis is a medical technology company focused on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults. NeurAxis is dedicated to advancing its IB-Stim therapy based on its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology through evidence-based research to drive adoption by the clinical and scientific communities.   With FDA clearance for functional abdominal pain associated with IBS in children and ongoing clinical trials for multiple other conditions, NeurAxis is focused on serving the unmet healthcare needs of children and adults. Founded in 2012, NeurAxis is committed to increasing awareness and broad access to its technology for children and adults.   The IB-Stim product provides equal to or greater efficacy and is much safer than standard pharmacotherapy. NeurAxis is adding to its existing base of written policy coverage with insurance providers.   #neuraxis #nyse #medtech #neuromodulation #IBstim #penfs #nrxs  Brian Carrico